TYRX, Inc., a leader in the commercialization of implantable drug-device union products, announced that it has enrolled its first patient in CENTURION, the first of two large scale, prospective, multicenter studies. CENTURION will enroll 2000 career at 50 clinical study sites across the U.S. Each patient is currently implanted with either a pacemaker, implantable cardioverter defibrillator (ICD) or a cardiac resynchronization therapy (CRT) device which will be replaced with a CRT device accompanied by AIGISRx...

More: - The rest...